In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 125 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]	Technology appraisal guidance	TBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]	Technology appraisal guidance	10 September 2025
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235	Technology appraisal guidance	TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]	Technology appraisal guidance	29 October 2025
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	NICE guideline	TBC
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]	Technology appraisal guidance	TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]	Technology appraisal guidance	TBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]	Technology appraisal guidance	4 February 2026
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317	Technology appraisal guidance	TBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]	Technology appraisal guidance	19 August 2025
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)	NICE guideline	TBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409	Technology appraisal guidance	TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	TBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma	Interventional procedures guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]	Technology appraisal guidance	21 August 2025
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]	Technology appraisal guidance	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC

Results per page

10
25
50
All